# Lyell Immunopharma

Source: https://onco.cc/companies/lyell-immunopharma/  
OnCo record `lyell-immunopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lyell makes next-generation CAR T-cell therapies designed to last longer in the body and resist exhaustion. Its lead product, ronde-cel, targets two proteins on lymphoma cells at once and is in pivotal trials for large B-cell lymphoma.

## Summary

Lyell Immunopharma is a late-stage clinical company developing CAR T-cell therapies engineered to resist exhaustion and retain stem-like qualities. Lead candidate rondecabtagene autoleucel (ronde-cel) is an autologous dual-targeting CD19/CD20 CAR T-cell product with an OR logic gate, manufactured with a process that enriches CD62L-positive cells. It is in two pivotal trials in relapsed or refractory large B-cell lymphoma, PiNACLE (third line or later) and PiNACLE-H2H (second line); no grade 3 or higher cytokine release syndrome was seen in more than 100 patients. Pivotal data are expected mid-2027 with a BLA planned for late 2027. Ronde-cel holds RMAT and Fast Track designations. LYL273 is a CAR T candidate in a phase 1/2 trial in metastatic colorectal cancer. Lyell runs its own LyFE manufacturing centre, held about $228 million in cash at 30 June 2026 and trades on Nasdaq as LYEL.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: South San Francisco, CA
- Type: cell-therapy
- Website: https://www.lyell.com
- Ticker: LYEL

## Notes

- No funding round sourced; the June 2021 IPO release was not located in EDGAR full-text search.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Lyell_Immunopharma
- Official website: https://www.lyell.com
- Q2 2026 results (8-K exhibit 99.1): https://www.sec.gov/Archives/edgar/data/1806952/000162828026054330/lyel-20260806x8kexx991.htm

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)
- drugs: [Rondecabtagene autoleucel](https://onco.cc/drugs/rondecabtagene-autoleucel/)
- trials: [A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy](https://onco.cc/trials/nct07188558/), [LYL273 for Patients With Relapsed or Refractory mCRC](https://onco.cc/trials/nct05319314/), [Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma](https://onco.cc/trials/nct05826535/)

---
JSON: https://onco.cc/api/v1/entities/lyell-immunopharma.json